About
BirchBioMed Inc.
BirchBioMed is a clinical stage biopharmaceutical company focused on developing treatments for scarring (fibrosis, i.e., the overproduction and insufficient breakdown (or remodeling) of ECM proteins, predominantly collagen and fibronectin, within an organ) and related skin disorders; certain autoimmune diseases; and organ fibrosis.
We hold the exclusive, worldwide, non-perpetual pharmaceutical licenses from the University of British Columbia for two scientific technologies, FS1/FS2 and AI-001.
Based on preclinical studies and clinical trials we have conducted to date, we believe these technologies hold the potential for significant medical breakthroughs in the treatment of certain debilitating conditions/disorders in need of novel, better solutions.
BirchBioMed Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Financial Highlights
Historical financial performance
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | Aug 12, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | Jul 1, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | May 1, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Apr 2, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Feb 13, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Dec 23, 2025 | [Cover] Draft Registration Statement |
| D/A | Oct 1, 2025 | Filing |
| D | Jul 11, 2025 | Notice of Exempt Offering of Securities |
| 1-Z | Jun 30, 2025 | Filing |
| 1-A-W | May 15, 2025 | Filing |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Mark S. Miller
Chief Executive Officer and Chairman
Jon S. Verbeck
Chief Financial Officer
Carlos Camozzi, M.D., Ph.D.
Chief Medical Officer
Susan Elliott
Chief Operating Officer and Director
Teresa Bair
Director
Charles N. Ellis, M.D.
Director
Joseph Sardano
Director
James M. Jenkins
Director
